Pajares, Bella <br/><br/>
Differential outcome of concurrent radiotherapy plus epidermal growth factor receptor inhibitors versus radiotherapy plus cisplatin in patients with human papillomavirus-related head and neck cancer.  [electronic resource] 

 -  BMC cancer  Jan 2013 
 - 26 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1471-2407 
<br/><br/><label>Standard No.: </label>10.1186/1471-2407-13-26  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antibodies, Monoclonal--therapeutic use<br/>Antibodies, Monoclonal, Humanized--therapeutic use<br/>Antineoplastic Agents--therapeutic use<br/>Carcinoma, Squamous Cell--metabolism<br/>Cetuximab<br/>Chemoradiotherapy<br/>Cisplatin--therapeutic use<br/>Cyclin-Dependent Kinase Inhibitor p16--metabolism<br/>DNA, Viral--metabolism<br/>Disease-Free Survival<br/>Dose Fractionation, Radiation<br/>ErbB Receptors--antagonists & inhibitors<br/>Female<br/>Gefitinib<br/>Head and Neck Neoplasms--metabolism<br/>Human papillomavirus 16--genetics<br/>Humans<br/>Kaplan-Meier Estimate<br/>Male<br/>Middle Aged<br/>Neoplasm Metastasis<br/>Neoplasm Recurrence, Local--metabolism<br/>Panitumumab<br/>Proportional Hazards Models<br/>Quinazolines--therapeutic use<br/>Retrospective Studies